Table 1 Demographic and disease specific characteristics of RA patients.
Mean/Median(±SD/IQR)or n (%) | |
|---|---|
n | 62 |
Mean age, (years) | 61.8 (13.4) |
Sex (no. of female, %) | 43/62 (69.4) |
Mean disease Duration (years) | 13.1 (8.7) |
Seropositive (CCP+) | 50/62 (80.6%) |
Surgery | |
Synovectomy | 30/62 (48.4) |
Joint Replacement/Arthrodesis | 32/62 (51.6) |
Medical treatment | |
Methotrexate | 18/62 (29.0%) |
Etanercept | 22/62 (35.5%) |
Adalimumab | 12/62 (19.3%) |
Certolizumab | 4/62 (6.4%) |
Infliximab | 4/62 (6.4%) |
Golimumab | 2/62 (3.2%) |
Prednisolon | 33/62 (53.2%) |
Synovial biopsies (joints) | |
Metacarpophalangeal joint | 12 (19.3%) |
Knee joint | 12 (19.3%) |
Hip joint | 10 (16.1%) |
Glenohumeral joint | 6 (9.6%) |
Cubital joint | 5 (8.1%) |
Metatarsophalangeal joint | 5 (8.1%) |
Proximal interphalangeal joint | 5 (8.1%) |
Upper ankle joint | 3 (4.8%) |
Talonavicular joint | 2 (3.2%) |
Carpometacarpal joint | 1 (1.6%) |
Tarsometatarsal joint | 1 (1.6%) |
Laboratory values | |
CRP (mg/l) median | 4 (1–10) |
